Immuron

Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment is involved in research and development projects performed in Australia, Israel, and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time).

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Immuron Travelan® continued strong sales growth

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC).

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline Insight, 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler's Diarrhea pipeline landscape is provided which includes the disease overview and Traveler's Diarrhea treatment guidelines.

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has received favourable feedback from the United States Food and Drug Administration (FDA) on the pre-IND (investigational new drug) information package to support the clinical development of IMM-529.

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Citizens

Cadrenal Therapeutics Inc

Elutia Inc

Euda Health Holdings Ltd

Cytomed Therapeutics Ltd

Gossamer Bio Inc

Geovax Labs

Intelligent Bio Solutions Inc

iQSTEL Inc.

Prospector LeddarTech Almalco

Nature's Miracle California Inc

Pure Cycle

Peraso

SunCar Technology Group Inc

22nd Century Group

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR) Silver Spring, MD, USA.

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024.

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on:

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529.

Immuron requests pre-IND meeting for IMM-529 with FDA filing

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today.

Immuron Board Changes

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024.

Immuron CEO Steven Lydeamore to present at Peak Sky High

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May.

Immuron Limited to Present at the Emerging Growth Conference

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests.

Immuron Director Resignation

MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT.

Immuron to host Live Virtual Event

Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter     Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcp Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter     USA FYTD Mar 2024 AUD$0.8 million up 35% on pcp Mar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarter Sales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Sales of Travelan® increased 250% to AUD $2.7 million FYTD Mar 2024 compared to AUD $0.8 million FYTD Mar 2023.

Immuron Travelan® sales continued strong growth

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint) 66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secondary endpoint) 83.3% statistically significant reduction in the number of subjects in the Travelan® group requiring early antibiotic treatment post challenge compared to the placebo (secondary endpoint) 100% of the subjects requiring IV fluids post challenge were in the placebo (secondary endpoint) 55.6% reduction in the number of subjects experiencing adverse events associated with the ETEC challenge observed in the Travelan® group compared to the placebo group (secondary endpoint) Phase 2 clinical study data supports the excellent safety and tolerability profile of Travelan® MELBOURNE, Australia, March 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli (ETEC). Immuron was awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense (ASX Announcement 12 January 2022) to perform a randomized double-blind placebo-controlled phase 2 controlled human infection model (CHIM) study to assist with evaluating a dosing regimen that is most suited to deployed US troops visiting developing countries.

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.

Immuron Presentation Australian Biologics Festival 2024

Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan® YTD Jan 2024 sales $2.1 million USA Travelan® YTD Jan 2024 sales $0.6 million Canadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Sales of Travelan® increased to AUD $2.1 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.

Immuron achieves record Travelan® sales

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia.

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Highlights: Record half yearly Travelan® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Australia Sales of Travelan® increased to AUD $1,853,048 in H1, FY24, compared to AUD $260,205 in H1, FY23.

Immuron achieves record half yearly Travelan® sales

Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completed Pre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company's clinical development portfolio. The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.

Immuron Clinical Trials Update

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis New CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers' diarrhea The in-patient stage of the study is anticipated to be completed by the end of December 2023 MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.

News for Immuron Stock (IMRN)